Annexon, Inc. Common Stock
Symbol: ANNX (NASDAQ)
Company Description:
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
- Today's Open: $3.02
- Today's High: $3.164
- Today's Low: $2.91
- Today's Volume: 280.03K
- Yesterday Close: $3.05
- Yesterday High: $3.14
- Yesterday Low: $2.91
- Yesterday Volume: 2.94M
- Last Min Volume: 12.51K
- Last Min High: $3.145
- Last Min Low: $3.136
- Last Min VWAP: $3.14494
- Name: Annexon, Inc. Common Stock
- Website: https://www.annexonbio.com
- Listed Date: 2020-07-24
- Location: BRISBANE, CA
- Market Status: Active
- CIK Number: 0001528115
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $335.15M
- Round Lot: 100
- Outstanding Shares: 109.89M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-04 | 4 | View |
2025-08-14 | 10-Q | View |
2025-08-14 | 8-K | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-06 | SCHEDULE 13G/A | View |
2025-08-01 | 4 | View |
2025-07-16 | 4 | View |
2025-07-16 | 4 | View |
2025-07-16 | 4 | View |
2025-07-14 | 144 | View |
2025-07-14 | 144 | View |
2025-07-14 | 144 | View |
2025-07-01 | 4 | View |
2025-06-25 | 8-K | View |
2025-06-09 | 4 | View |
2025-06-09 | 4 | View |
2025-06-09 | 4 | View |
2025-06-09 | 4 | View |
2025-06-09 | 4 | View |
2025-06-09 | 4 | View |